EHR UPDATE CHECKLIST

xofluza® (baloxavir marboxil) tablets 40mg 80mg

Ensure XOFLUZA is up to date in your EHR system

- [ ] **Confirm that your EHR drug database is up to date for XOFLUZA**
  - If your EHR system does not display single-tablet configurations (see table below), continue reviewing this checklist to determine what steps can be taken
- [ ] **Determine how your EHR system updates are made and when the next update will occur**
  - If updates are made automatically, your EHR system will push updates within a designated timeframe. Determine how often this happens
  - If you have a practice-triggered EHR system, someone may need to manually download the latest drug information for XOFLUZA. Determine when the next update is expected and who can help trigger this update
  - If needed, notify the IT department that the database is out of date and ask if the update process can be expedited
- [ ] **Is your system algorithm- or formulary-driven?**
  - A prescriber may need to search for XOFLUZA if it does not appear when the diagnosis is entered
  - Ask the prescriber if they can create favorites in the EHR system to easily locate single-tablet XOFLUZA
  - Remind the prescriber there may be historical comments in the XOFLUZA order template that may need review
  - To prevent callbacks, request the prescriber to clarify the total dose in the order comments

CODING[1]

National Drug Code (NDC)	Product Description
Single-dose tablets	
50242-860-01	1 x 40-mg tablet (total dose of 40 mg) per blister card in secondary packaging
50242-877-01	1 x 80-mg tablet (total dose of 80 mg) per blister card in secondary packaging

Note: Two-tablet configurations may be present in EHR systems and local pharmacies.

Indication

XOFLUZA is an influenza virus polymerase acidic (PA) endonuclease inhibitor indicated for:
Treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours and who are:

- Otherwise healthy, or
- At high risk of developing influenza-related complications

Post-exposure prophylaxis (PEP) of influenza in patients 12 years of age and older following contact with an individual who has influenza.

Limitations of Use

Influenza viruses change over time, and factors such as the virus type or subtype, emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating influenza virus strains when deciding whether to use XOFLUZA.

Please see next page for additional Important Safety Information and click here for full Prescribing Information.

Important Safety Information

Contraindications

XOFLUZA is contraindicated in patients with a history of hypersensitivity to baloxavir marboxil or any of its ingredients. Serious allergic reactions have included anaphylaxis, angioedema, urticaria, and erythema multiforme.

Warnings and Precautions

Hypersensitivity: Cases of anaphylaxis, urticaria, angioedema, and erythema multiforme have been reported in postmarketing experience with XOFLUZA. Appropriate treatment should be instituted if an allergic-like reaction occurs or is suspected.

Risk of bacterial infections: There is no evidence of the efficacy of XOFLUZA in any illness caused by pathogens other than influenza viruses. Serious bacterial infections may begin with influenza-like symptoms or may coexist with, or occur as, a complication of influenza. XOFLUZA has not been shown to prevent such complications. Prescribers should be alert to potential secondary bacterial infections and treat them as appropriate.

Adverse Reactions

The most common adverse reactions (≥1%) in clinical studies for acute uncomplicated influenza were diarrhea (3%), bronchitis (3%), nausea (2%), sinusitis (2%), and headache (1%).

The most common adverse reaction in a clinical study for post-exposure prophylaxis (PEP) was nasopharyngitis (6%).

Drug Interactions

Polyvalent cations: Coadministration with polyvalent cation-containing products may decrease plasma concentrations of baloxavir, which may reduce XOFLUZA efficacy. Avoid coadministration of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc).

Vaccines: The concurrent use of XOFLUZA with intranasal live attenuated influenza vaccine (LAIV) has not been evaluated. Concurrent administration of antiviral drugs may inhibit viral replication of LAIV and, thereby, decrease the effectiveness of LAIV vaccination. Interactions between inactivated influenza vaccines and XOFLUZA have not been evaluated.

For additional important safety information, please see the XOFLUZA full Prescribing Information.

You are encouraged to report side effects to Genentech by calling 1-888-835-2555 or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.

Reference: 1. XOFLUZA [Prescribing Information]. South San Francisco, CA. Genentech USA, Inc.; 2021.

Genentech
A Member of the Roche Group

xofluza® (baloxavir marboxil) tablets 40 mg 80 mg